Migraine: integrated approaches to clinical management and emerging treatments

Migraine is a highly disabling neurological disorder that directly affects more than 1 billion individuals worldwide. Available treatment options differ between countries and include acute, preventive, and non-pharmacological therapies. Because of major progress in the understanding of migraine pathogenesis, novel mechanism-based medications have emerged and expanded the armamentarium of treatments. We provide a comprehensive overview of the current standard of care that will enable informed clinical management. First, we discuss the efficacy, tolerability, and safety profile of various pharmacological therapies for acute and preventive treatment of migraine. Second, we review the current knowledge on non-pharmacological therapies, such as neuromodulation and biobehavioural approaches, which can be used for a multidisciplinary approach to clinical management. Third, we emphasise that any effective treatment strategy starts with building a therapeutic plan tailored to individual clinical characteristics, preferences, and needs. Finally, we explore the outlook of emerging mechanism-based treatments that could address unmet challenges in clinical management of migraine.Paroxysmal Cerebral Disorder

Migraine: integrated approaches to clinical management and emerging treatments

Migraine is a highly disabling neurological disorder that directly affects more than 1 billion individuals worldwide. Available treatment options differ between countries and include acute, preventive, and non-pharmacological therapies. Because of major progress in the understanding of migraine pathogenesis, novel mechanism-based medications have emerged and expanded the armamentarium of treatments. We provide a comprehensive overview of the current standard of care that will enable informed clinical management. First, we discuss the efficacy, tolerability, and safety profile of various pharmacological therapies for acute and preventive treatment of migraine. Second, we review the current knowledge on non-pharmacological therapies, such as neuromodulation and biobehavioural approaches, which can be used for a multidisciplinary approach to clinical management. Third, we emphasise that any effective treatment strategy starts with building a therapeutic plan tailored to individual clinical characteristics, preferences, and needs. Finally, we explore the outlook of emerging mechanism-based treatments that could address unmet challenges in clinical management of migraine. © 2021 Elsevier Lt

Latin American consensus on guidelines for chronic migraine treatment

Chronic migraine is a condition with significant prevalence all around the world and high socioeconomic impact, and its handling has been challenging neurologists. Developments for understanding its mechanisms and associated conditions, as well as that of new therapies, have been quick and important, a fact which has motivated the Latin American and Brazilian Headache Societies to prepare the present consensus. The treatment of chronic migraine should always be preceded by a careful diagnosis review; the detection of possible worsening factors and associated conditions; the stratification of seriousness/ impossibility to treat; and monitoring establishment, with a pain diary. The present consensus deals with pharmacological and nonpharmacological forms of treatment to be used in chronic migraine

Latin American Consensus On Guidelines For Chronic Migraine Treatment

Chronic migraine is a condition with significant prevalence all around the world and high socioeconomic impact, and its handling has been challenging neurologists. Developments for understanding its mechanisms and associated conditions, as well as that of new therapies, have been quick and important, a fact which has motivated the Latin American and Brazilian Headache Societies to prepare the present consensus. The treatment of chronic migraine should always be preceded by a careful diagnosis review; the detection of possible worsening factors and associated conditions; the stratification of seriousness/ impossibility to treat; and monitoring establishment, with a pain diary. The present consensus deals with pharmacological and nonpharmacological forms of treatment to be used in chronic migraine.717478486(2004) International Classification of Headache Disorders, 24, pp. S1-S160. , International Headache Society Classification Subcommittee 2nd edition. Cephalalgia(2011) Atlas of Headache Disorders and Resources in the World, , World Health Organization Geneva: WHO2011Stovner, L.J., Hagen, K., Jensen, R., The global burden of headache: A documentation of headache prevalence and disability worldwide (2007) Cephalalgia, 27, pp. 193-210Natoli, J.L., Manack, A., Dean, B., Global prevalence of chronic migraine: A systematic review (2010) Cephalalgia, 30, pp. 599-609Lipton, R.B., Bigal, M.E., Diamond, M., Migraine prevalence, disease burden, and the need for preventive therapy (2007) Neurology, 68, pp. 343-349. , AMPP Advisory GroupSilva Junior, A.A., Tavares, R.M., Lara, R.R., Faleiros, B.E., Gomez, R.S., Teixeira, A.L., Frequency of types of headache in the tertiary care center of the hospital das clinicas of the universidade federal de minas gerais, MG, Brazil (2012) Rev Assoc Med Bras, 58, pp. 709-713Davies, P., Medication overuse headache: A silent pandemic (2012) Pain, 153, pp. 7-8Altena, M., Katsarava, Z., Nappi, G., COMOESTAS consortium. From drug-induced headache to medication overuse headache. A short epidemiological review, with a focus on latin American countries (2009) J Headache Pain, 10, pp. 71-76Manack, A., Buse, D.C., Serrano, D., Türkei, C.C., Lipton, R.B., Rates, predictors, and consequences of remission from chronic migraine to episodic migraine (2011) Neurology, 76, pp. 711-718Buse, D.C., Manack, A., Serrano, D., Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers (2010) J Neurol Neurosurg Psychiatry, 81, pp. 428-432Stokes, M., Becker, W.J., Lipton, R.B., Cost of health care among patients with chronic and episodic migraine in canada and the USA: Results from the international burden of migraine study (IBMS) (2011) Headache, 51, pp. 1058-1077Cevoli, S., Sancisi, E., Pierangeli, G., Chronic daily headache: Risk factors and pathogenic considerations (2006) Neurol Sci, 27, pp. S168-S173Silberstein, S.D., Upton, R.B., Sliwinski, M., Classification of daily and near-daily headaches: Field trial of revised IHS criteria (1996) Neurology, 47, pp. 871-875Saper, J.R., The mixed headache syndrome: A new perspective (1982) Headache, 22, pp. 284-286Mathew, N.T., Transformed migraine (1993) Cephalalgia, 13, pp. S78-S83Olesen, J., Bousser, M.G., Diener, H.C., Headache classification committee. New appendix criteria open for a broader concept of chronic migraine (2006) Cephalalgia, 26, pp. 742-746Gl, S., Park, J.W., Shin, H.E., Differences in clinical features and disability according to the frequency of medication use in patients with chronic migraine (2012) J Clin Neurol, 8, pp. 198-203Pozo-Rosich, P., Migrana crónica: Epidemiologia e impacto (2012) Rev Neurol, 54, pp. S3-S11Goadsby, P.J., Charbit, A.R., Andreou, A.P., Neurobiology of migraine (2009) Neuroscience, 161, pp. 327-341Lipton, R.B., Tracing transformation: Chronic migraine classification, progression, and epidemiology (2009) Neurology, 72, pp. S3-S7Srikiatkhachom, A., Chronic daily headache: A scientist's perspective (2002) Headache, 42, pp. 523-537Kruit, M.C., Van Büchern, M.A., Launer, U., Migraine is associated with an increased risk of deep white matter lesions, subclinical posterior circulation infarcts and brain iron accumulation: The population-based MRI CAMERA study (2010) Cephalalgia, 30, pp. 129-136Spector, J.T., Kahn, S.R., Jones, M.R., Migraine headache and ischemic stroke risk: An updated meta-analysis (2010) Am J Med, 123, pp. 612-624Chen, Y.C., Tang, C.H., Ng, K., Comorbidity profiles of chronic migraine sufferers in a national database in Taiwan (2012) J Headache Pain, 13, pp. 311-319Yoon, G., Baggaley, S., Bacchetti, P., Clinic-based study of family history of vascular risk factors and migraine (2005) J Headache Pain, 6, pp. 412-416Bigal, M.E., Kurth, T., Santanello, N., Migraine and cardiovascular disease: A population-based study (2010) Neurology, 74, pp. 628-635Tembl, J., Lago, A., Sevilla, T., Migraine, patent foramen ovale and migraine triggers (2007) J Headache Pain, 8, pp. 07-12Garg, P., Servoss, S.J., Wu, J.C., Lack of association between migraine headache and patent foramen ovale: Results of a case-control study (2010) Circulation, 121, pp. 1406-1412Merikangas, K.R., Angst, J., Isler, H., Migraine and psychopathology. Results of the zurich cohort study of young adults (1990) Arch Gen Psychiatry, 47, pp. 849-853Teixeira, A.L., Costa, E.A., Alberto Da Silva Jr., A., Psychiatric comorbidities of chronic migraine in community and tertiary care clinic samples (2012) J Headache Pain, 13, pp. 551-555Ottman, R., Lipton, R.B., Ettinger, A.B., Comorbidities of epilepsy: Results from the epilepsy comorbidities and health (EPIC) survey (2011) Epilepsia, 52, pp. 308-315Von Brevem, M., Neuhauser, H., Epidemiological evidence for a link between vertigo and migraine (2011) J Vestib Res, 21, pp. 299-304Kister, I., Caminero, A.B., Herbert, J., Tension-type headache and migraine in multiple sclerosis (2010) Curr Pain Headache Rep, 14, pp. 441-448De Tommaso, M., Sardaro, M., Serpino, C., Fibromyalgia comorbidity in primary headaches (2009) Cephalalgia, 29, pp. 453-464Peres, M.R., Young, W.B., Kaup, A.O., Fibromyalgia is common in patients with transformed migraine (2001) Neurology, 57, pp. 1326-1328Riedl, A., Schmidtmann, M., Stengel, A., Somatic comorbidities of irritable bowel syndrome: A systematic analysis (2008) J Psychosom Res, 64, pp. 573-582Stuginski-Barbosa, J., Macedo, H.R., Bigal, M.E., Signs of temporomandibular disorders in migraine patients: A prospective, controlled study (2010) Clin J Pain, 26, pp. 418-421Goncalves, D.A., Camparis, C.M., Speciali, J.G., Temporomandibular disorders are differentially associated with headache diagnoses: A controlled study (2011) Clin J Pain, 27, pp. 611-615Katsarava, Z., Schneeweiss, S., Kurth, T., Incidence and predictors for chronicity of headache in patients with episodic migraine (2004) Neurology, 62, pp. 788-790Bigal, M.E., Serrano, D., Buse, D., Acute migraine medications in evolution from episodic to chronic migraine: A longitudinal population-based study (2008) Headache, 48, pp. 1157-1168Scher, A.I., Stewart, W.F., Ricci, J.A., Factors associated with the onset and remission of chronic daily headache in a population-based study (2003) Pain, 106, pp. 81-89Bigal, M.E., Lipton, R.B., Obesity is a risk factor for transformed migraine but not chronic tension-type headache (2006) Neurology, 67, pp. 252-257Al, S., Lipton, R.B., Stewart, W.F., Habitual snoring as a risk factor for chronic daily headache (2003) Neurology, 60, pp. 1366-1368Scher, A.I., Stewart, W.F., Lipton, R.B., Caffeine as a risk factor for chronic daily headache: A population-based study (2004) Neurology, 63, pp. 2022-2027Tietjen, G.E., Peterlin, B.L., Brandes, J.L., Depression and anxiety: Effect on the migraine-obesity relationship (2007) Headache, 47, pp. 866-875Scher, A.I., Stewart, W.F., Buse, D., Major life changes before and after the onset of chronic daily headache: A population-based study (2008) Cephalalgia, 28, pp. 868-876Lipton, R.B., Silberstein, S.D., Saper, J.R., Why headache treatment fails (2003) Neurology, 60, pp. 1064-1070Yu, S., Liu, R., Zhao, G., The prevalence and burden of primary headaches in China: A population-based door-to-door survey (2012) Headache, 52, pp. 582-591Stuginski-Barbosa, J., Dach, F., Bigal, M., Chronic pain and depression in the quality of life of women with migraine - A controlled study (2012) Headache, 52, pp. 400-408Valença, M.M., Valença, L.P.A.A., Bordini, C., Cefaleia de "dificil controle," (2003) MigrCefaleias, 6, pp. 117-120Silberstein, S.D., Dodick, D.W., Pearlman, S., Defining the pharmacologically intractable headache for clinical trials and clinical practice (2010) Headache, 50, pp. 1499-1506Recomendacöes para o tratamento da crise migranosa (2000) Arq Neuropsiquiatr, 58, pp. 371-389. , Consensu da Sociedade BrasileiraRecomendacöes para o tratamento profilático da migránea (2002) Arq Neuropsiquiatr, 60, pp. 159-169. , Consensu da Sociedade BrasileiraPascual, J., Migrana crónica: Tratamiento (2012) Rev Neurol, 54, pp. S31-S38Schwartz, T.H., Karpistikiy, W., Sohn, R.S., Intravenous valproate sodium in the treatment of daily headache (2002) Headache, 42, pp. 519-522Demirkaya, S., Vural, O., Dora, B., Efficacy of intravenous magnesium sulfate in the treatment of acute migraine attacks (2001) Headache, 41, pp. 171-177Paemeleire, K., Crevits, L., Goadsby, P.J., Practical management of medication-overuse headache (2006) Acta Neurol Belg, 106, pp. 43-51Lane, R.L., Ross, R., Intravenous chlorpromazine - Preliminary results in acute migraine (1985) Headache, 25, pp. 302-304Monzillo, P.H., Nemoto, P.H., Costa, A.R., Acute treatment of migraine in emergency room: Comparative study between dexametasone and haloperidol. Preliminary results (2004) Arq Neuropsiquiatr, 62, pp. 513-518Hill, C.H., Miner, J.R., Martel, M.L., Olanzapine versus dropendol for the treatment of primary headache in the emergency department (2008) Acad Emerg Med, 15, pp. 806-811Silberstein, S.B., Peres, M.R., Olanzapine in the treatment of refractory headache (2002) Headache, 42, pp. 515-518Mendes, P.M., Silberstein, S.D., Young, W.B., Intravenous propofol in the treatment of refractory headache (2002) Headache, 42, pp. 638-641Dusitanond, P., Young, W.B., Neuroleptics and migraine (2009) Cent Nerv Syst Agents Med Chem, 9, pp. 63-70Krymchantowski, A.V., Jevoux, C., Moreira, P.R., An open pilot study assessing the benefits of quetiapine for the prevention of migraine refractory to the combination of atenolol, nortriptyline, and flunarizine (2010) Pain Med, 11, pp. 48-52Obermann, M., Katsarava, Z., Management of medication-overuse headache (2007) Expert Rev Neurother, 7, pp. 1145-1155Pageler, L., Katsarava, Z., Diener, H.C., Prednisone vs. Placebo in withdrawal therapy following medication overuse headache (2008) Cephalalgia, 28, pp. 152-156Katsarava, Z., Holle, D., Diener, H.C., Medication overuse headache (2009) Curr Neurol Neurosci Rep, 9, pp. 115-119Zeeberg, P., Olesen, J., Jensen, R., Discontinuation of medication overuse in headache patients: Recovery of therapeutic responsiveness (2006) Cephalalgia, 26, pp. 1192-1198Rossi, R., Jensen, R., Nappi, G., A narrative review on the management of medication overuse headache: The steep road from experience to evidence (2009) J Headache Pain, 10, pp. 407-417Dodick, D.W., Türkei, C.C., DeGryse, R.E., Onabotulinumtoxma for treatment of chronic migraine: Pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program (2010) Headache, 50, pp. 921-936. , PREEMPT Chronic Migraine Study GroupDiener, H.C., Dodick, D.W., Aurora, S.K., Onabotulinumtoxin A for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial (2010) Cephalalgia, 30, pp. 804-814. , PREEMPT 2 Chronic Migraine Study GroupSilberstein, S.D., Lipton, R.B., Dodick, D.W., Efficacy and safety of topiramate for the treatment of chronic migraine: A randomized, double-blind, placebo-controlled trial (2007) Headache, 47, pp. 170-180. , TopiramateChronic Migraine Study GroupSilvestrini, M., Bartolini, M., Coccia, M., Topiramate in the treatment of chronic migraine (2003) Cephalalgia, 23, pp. 820-824Diener, H.C., Bussone, G., Van Oene, J.C., Topiramate reduces headache days in chronic migraine: A randomized, double-blind, placebo-controlled study (2007) Cephalalgia, 27, pp. 814-823. , TOPMAT-MIG-201 (TOP-CHROME) Study GroupYurekli, V.A., Akhan, G., Kutluhan, S., The effect of sodium valproate on chronic daily headache and its subgroups (2008) J Headache Pain, 9, pp. 37-41Silberstein, S.D., Neto, W., Schmitt, J., Topiramate in migraine prevention: Results of a large controlled trial (2004) Arch Neurol, 61, pp. 490-495. , MIGR-001 Study GroupBrandes, J.L., Saper, J.R., Diamond, M., Topiramate for migraine prevention: A randomized controlled trial (2004) JAMA, 291, pp. 965-973. , MIGR-002 Study GroupSilberstein, S.D., Hulihan, J., Karim, M.R., Efficacy and tolerability of topiramate 200 mg/d in the prevention of migraine with/without aura in adults: A randomized, placebo-controlled, double-blind, 12-week pilot study (2006) Clin Ther, 28, pp. 1002-1011Silberstein, S., Lipton, R., Dodick, D., Topiramate treatment of chronic migraine: A randomized, placebo-controlled trial of quality of life and other efficacy measures (2009) Headache, 49, pp. 1153-1162Hering, R., Kuntzky, A., Sodium valproate in the prophylactic treatment of migraine: A double-blind study versus placebo (1992) Cephalalgia, 12, pp. 81-84Silberstein, S.D., Collins, S.D., Long-term safety of depakote in headache prophylaxis study group (1999) Headache, 39, pp. 633-643. , Safety of divalproex sodium in migraine prophylaxis: an open-label, long-term studyFreitag, F.G., Collins, S.D., Carlson, H.A., Depakote, E.R., A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis (2002) Neurology, 58, pp. 1652-1659. , Migraine Study GroupRowe, A., Lachinski, R., Rizelio, V., Hospital management of intractable headaches. The institute de neurologia de curitiba approach (2011) Head Med, 2, pp. 194-199Lionetto, L., Negro, A., Palmisani, S., Emerging treatment for chronic migraine and refractory chronic migraine (2012) Expert Opin Emerg Drugs, 17, pp. 393-406Aurora, S.K., Dodick, D.W., Türkei, C.C., Onabotulinumtox in A for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial (2010) Cephalalgia, 30, pp. 793-803. , PREEMPT 1 Chronic Migraine Study GroupDiener, H.C., Dodick, D.W., Aurora, S.K., Onabotulinumtox in A for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial (2010) Cephalalgia, 30, pp. 804-814. , PREEMPT 2 Chronic Migraine Study GroupDiener, H.C., Detoxification for medication overuse headache is not necessary (2012) Cephalalgia, 32, pp. 423-427Aurora, S., Letter to the editor (2011) Cephalalgia, 31, pp. 378-379Cutrer, F.M., Mathew, P., Garza, I., Cutaneous allodynia as a prognostic factor in the treatment of migraine with botulinum toxin (abstract n. PO-69) (2010) 52nd Annual Service Meeting of the American Headache Society Los Angeles;Frampton, J.E., Onabotulinumtox in A (BOTOX*): A review of its use in the prophylaxis of headaches in adults with chronic migraine (2012) Drugs, 72, pp. 825-845Mathew, N.T., Jaffri, S.F., Adouble-blind comparison of onabotulinumtox in A (BOTOX) and topiramate (T0PAMAX) for the prophylactic treatment of chronic migraine: A pilot study (2009) Headache, 49, pp. 1466-1478Yang, C.P., Chang, M.H., Liu, P.E., Acupuncture versus topiramate in chronic migraine prophylaxis: A randomized clinical trial (2011) Cephalalgia, 31, pp. 1510-1521Rossi, R., Di Lorenzo, G., Malpezzi, M.G., Prevalence, pattern and predictors of use of complementary and alternative medicine (CAM) in migraine patients attending a headache clinic in Italy (2005) Cephalalgia, 25, pp. 493-506Gaul, C., Eismann, R., Schmidt, T., Use of complementary and alternative medicine in patients suffering from primary headache disorders (2009) Cephalalgia, 29, pp. 1069-1078Wells, R.E., Bertisch, S.M., Buettner, C., Complementary and alternative medicine use among adults with migraines/severe headaches (2011) Headache, 51, pp. 1087-1097Kristoffersen, E.S., Grande, R.B., Aaseth, K., Management of primary chronic headache in the general population: The akershus study of chronic headache (2012) J Headache Pain, 13, pp. 113-12

Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019

Background Given the projected trends in population ageing and population growth, the number of people with dementia is expected to increase. In addition, strong evidence has emerged supporting the importance of potentially modifiable risk factors for dementia. Characterising the distribution and magnitude of anticipated growth is crucial for public health planning and resource prioritisation. This study aimed to improve on previous forecasts of dementia prevalence by producing country-level estimates and incorporating information on selected risk factors. Methods We forecasted the prevalence of dementia attributable to the three dementia risk factors included in the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 (high body-mass index, high fasting plasma glucose, and smoking) from 2019 to 2050, using relative risks and forecasted risk factor prevalence to predict GBD risk-attributable prevalence in 2050 globally and by world region and country. Using linear regression models with education included as an additional predictor, we then forecasted the prevalence of dementia not attributable to GBD risks. To assess the relative contribution of future trends in GBD risk factors, education, population growth, and population ageing, we did a decomposition analysis. Findings We estimated that the number of people with dementia would increase from 57·4 (95% uncertainty interval 50·4–65·1) million cases globally in 2019 to 152·8 (130·8–175·9) million cases in 2050. Despite large increases in the projected number of people living with dementia, age-standardised both-sex prevalence remained stable between 2019 and 2050 (global percentage change of 0·1% [–7·5 to 10·8]). We estimated that there were more women with dementia than men with dementia globally in 2019 (female-to-male ratio of 1·69 [1·64–1·73]), and we expect this pattern to continue to 2050 (female-to-male ratio of 1·67 [1·52–1·85]). There was geographical heterogeneity in the projected increases across countries and regions, with the smallest percentage changes in the number of projected dementia cases in high-income Asia Pacific (53% [41–67]) and western Europe (74% [58–90]), and the largest in north Africa and the Middle East (367% [329–403]) and eastern sub-Saharan Africa (357% [323–395]). Projected increases in cases could largely be attributed to population growth and population ageing, although their relative importance varied by world region, with population growth contributing most to the increases in sub-Saharan Africa and population ageing contributing most to the increases in east Asia. Interpretation Growth in the number of individuals living with dementia underscores the need for public health planning efforts and policy to address the needs of this group. Country-level estimates can be used to inform national planning efforts and decisions. Multifaceted approaches, including scaling up interventions to address modifiable risk factors and investing in research on biological mechanisms, will be key in addressing the expected increases in the number of individuals affected by dementia

The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019

Background In estimating the global burden of cancer, adolescents and young adults with cancer are often overlooked, despite being a distinct subgroup with unique epidemiology, clinical care needs, and societal impact. Comprehensive estimates of the global cancer burden in adolescents and young adults (aged 15–39 years) are lacking. To address this gap, we analysed results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, with a focus on the outcome of disability-adjusted life-years (DALYs), to inform global cancer control measures in adolescents and young adults. Methods Using the GBD 2019 methodology, international mortality data were collected from vital registration systems, verbal autopsies, and population-based cancer registry inputs modelled with mortality-to-incidence ratios (MIRs). Incidence was computed with mortality estimates and corresponding MIRs. Prevalence estimates were calculated using modelled survival and multiplied by disability weights to obtain years lived with disability (YLDs). Years of life lost (YLLs) were calculated as age-specific cancer deaths multiplied by the standard life expectancy at the age of death. The main outcome was DALYs (the sum of YLLs and YLDs). Estimates were presented globally and by Socio-demographic Index (SDI) quintiles (countries ranked and divided into five equal SDI groups), and all estimates were presented with corresponding 95% uncertainty intervals (UIs). For this analysis, we used the age range of 15–39 years to define adolescents and young adults. Findings There were 1·19 million (95% UI 1·11–1·28) incident cancer cases and 396 000 (370 000–425 000) deaths due to cancer among people aged 15–39 years worldwide in 2019. The highest age-standardised incidence rates occurred in high SDI (59·6 [54·5–65·7] per 100 000 person-years) and high-middle SDI countries (53·2 [48·8–57·9] per 100 000 person-years), while the highest age-standardised mortality rates were in low-middle SDI (14·2 [12·9–15·6] per 100 000 person-years) and middle SDI (13·6 [12·6–14·8] per 100 000 person-years) countries. In 2019, adolescent and young adult cancers contributed 23·5 million (21·9–25·2) DALYs to the global burden of disease, of which 2·7% (1·9–3·6) came from YLDs and 97·3% (96·4–98·1) from YLLs. Cancer was the fourth leading cause of death and tenth leading cause of DALYs in adolescents and young adults globally. Interpretation Adolescent and young adult cancers contributed substantially to the overall adolescent and young adult disease burden globally in 2019. These results provide new insights into the distribution and magnitude of the adolescent and young adult cancer burden around the world. With notable differences observed across SDI settings, these estimates can inform global and country-level cancer control efforts